Get the Stockscreener App
7.72
2.28%
-0.18
Pre-market:
7.70
-0.02
-0.26%
Sagimet Biosciences Inc stock is traded at $7.72, with a volume of 1.29M.
It is down -2.28% in the last 24 hours and up +45.11% over the past month.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.90
Open:
$7.93
24h Volume:
1.29M
Relative Volume:
0.97
Market Cap:
$476.72M
Revenue:
$2.00M
Net Income/Loss:
$-51.04M
P/E Ratio:
-4.8892
EPS:
-1.579
Net Cash Flow:
$-45.65M
1W Performance:
-11.77%
1M Performance:
+45.11%
6M Performance:
-0.64%
1Y Performance:
+115.04%
1-Day Range:
$7.47
$8.00
1-Week Range:
$7.36
$8.85
52-Week Range:
$3.08
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.72 | 476.72M | 2.00M | -51.04M | -45.65M | -1.579 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-03-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Does Sagimet Biosciences Inc. (SGMT) have the potential to rally 241.77% as Wall Street analysts expect? - MSN
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy? - sharewise.com
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect? - Yahoo Finance
Sagimet Biosciences shares jump 30% on acne trial expansion plans - MSN
Sagimet Biosciences Price Target Raised to $49.00/Share From $28.00 by Canaccord Genuity - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sagimet Biosciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating - marketscreener.com
Sagimet Therapeutics: Buy Rating Reiterated on Denifanstat’s First-Line Acne Potential; $28 Price Target Unchanged - TipRanks
Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise - MarketBeat
Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00 - MarketBeat
Why Is Sagimet Biosciences Stock Trading Higher On Monday? - Sahm
Sagimet Biosciences offers 29.17 million shares of series A common stockSEC filing - marketscreener.com
Sagimet Biosciences Announces Major Equity Offering for Pipeline - TipRanks
Sagimet Biosciences | 424B5: Prospectus - Moomoo
Sagimet Biosciences | 8-K: Current report - Moomoo
Sagimet Biosciences (NASDAQ: SGMT) prices $164.5M equity raise to fund trials - Stock Titan
Sagimet Biosciences (NASDAQ: SGMT) raises $175M to fund Phase 3 denifanstat - Stock Titan
SGMT - Finviz
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences rockets 30% on pricing $175M equity offering - MSN
Sagimet prices $175M stock offering to fund acne drug trials By Investing.com - Investing.com India
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push - TechStock²
Sagimet prices $175M stock offering to fund acne drug trials - Investing.com UK
Why Sagimet Biosciences Stock Is Soaring Today - AOL.com
Oppenheimer raises Sagimet stock price target on acne focus - Investing.com UK
Oppenheimer raises Sagimet stock price target on acne focus By Investing.com - Investing.com South Africa
Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans - Yahoo Finance
SGMT stock surged 40% and breached 200-DMA for the first time in nearly 3 months – what’s got retail buzzing? - MSN
Sagimet Biosciences surges as $175M equity financing and acne-focused pipeline update reset the runway narrative - Quiver Quantitative
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Sagimet Biosciences Advances Denifanstat and TVB-3567 as Novel FASN Inhibitors for Moderate to Severe Acne and MASH Treatment 23469 - Minichart
Sagimet Biosciences Advances Denifanstat and TVB-3567 as Novel FASN Inhibitors for Moderate to Severe Acne and MASH Treatment (2026 Update) - Minichart
Sagimet Biosciences (SGMT) Jumps As MASH Data Buzz Builds - StocksToTrade
Sagimet Biosciences to Fund Phase 3 Acne Trial in US With $175 Million Offering - marketscreener.com
Sagimet Biosciences SGMT Gains Attention On MASH Data - timothysykes.com
Sagimet plans U.S. Phase 3 acne trial in second half of 2026 - Investing.com UK
Morning Market Movers: SGMT, CMPX, ORKA, MANE See Big Swings - RTTNews
Sagimet Updates Investor Presentation After Key Clinical Milestones - TipRanks
Sagimet Highlights Pipeline Progress and Strategic Corporate Developments - TipRanks
Sagimet Biosciences stock surges 30% on acne trial plans By Investing.com - Investing.com South Africa
Sagimet plans U.S. Phase 3 acne trial in second half of 2026 By Investing.com - Investing.com South Africa
Sagimet Biosciences stock surges 30% on acne trial plans - Investing.com
Sagimet Biosciences to advance denifanstat to Phase 3 trial for U.S. acne market after China data - Traders Union
Sagimet Biosciences (SGMT) furnishes updated investor presentation via Form 8-K - Stock Titan
Sagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 Million - Quiver Quantitative
Sagimet raises $175M, says cash now funds acne programs through 2028 - Stock Titan
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock - GlobeNewswire
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):